ARPA‑H awarded BioCurie up to $9.3 million to develop an AI‑powered digital platform designed to accelerate and standardize gene therapy manufacturing across viral and non‑viral modalities. BioCurie will build predictive models, integrate real‑world process data, and partner with CDMOs and academic centers (including St. Jude and Center for Breakthrough Medicines) to validate digital twins for process development. The program targets reduced cycle times and improved reproducibility to address manufacturing bottlenecks that limit gene‑therapy access. ARPA‑H framed the award as part of a push to de‑risk scale‑up and reduce costs for genomic medicines.